3Wann LS, Curtis AB, Anuary CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrilla- tion (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation,2011,123: 104- 123.
4Zung WW. A self-rating depression scale. Arch Gen Psychiatry, 1965,12 : 63-70.
5Zung WW. A rating instrument for anxiety disorders. Psychoso- matics, 1971,12:371-379.
6Fang Y, Yuan C, Xu Y, et al. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psy- chopharmacol, 2010,30 : 357-364.
7Ware JJ, Sherbourne CD. The MOS 36-item short-form health mrvey (SF-36). I. Conceptual framework and item selection. Med Care, 1992,30: 473-483.
8周玉杰.冠状动脉粥样硬化性心脏病诊断标准2010.中华人民共和国卫生部.
9Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001,285 : 2370-2375.
10Ezekowitz MD, Netrebko PI. Anticoagulation in management of atrial fibrillation. Curr Opin Cardiol, 2003,18 : 26-31.
